Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03888053
Other study ID # BB-101-001A
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 28, 2018
Est. completion date December 31, 2023

Study information

Verified date April 2024
Source Blue Blood Biotech Corp.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, sequential dose escalation study in diabetic subjects with a diabetic lower leg or foot ulcer. All subjects will receive standard-of-care ulcer treatment from screening through the last study visit.


Description:

This is a randomized, double-blind, placebo-controlled, sequential dose escalation study in diabetic subjects with a diabetic lower leg or foot ulcer. All subjects will receive standard-of-care ulcer treatment from screening through the last study visit. The study will be conducted at multiple investigational sites located in Taiwan. Additional sites and countries may be added during the course of the study if required.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date December 31, 2023
Est. primary completion date December 1, 2021
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Male or female, 20 years of age and older. - Type 1 or type 2 diabetes mellitus. - Glycosylated hemoglobin (HbA1c) of =12%. - A target ulcer on the lower leg or foot that meets the following criteria at screening: 1. located below knees, 2. Area of 0.5 - 10.0 cm^2 following sharp debridement , as measured at Visit 1 and confirmed at Visit 2, 3. Extending through the epidermis and dermis but not involving bone, tendon or ligament, 4. Present for =4 weeks prior to Visit 1 despite appropriate care, and 5. Ulcer without clinical signs and symptoms of infection. - Adequate arterial blood supply to the lower leg or foot under study, to be measured either by doppler ultrasonography, ankle brachial pressure index (ABPI) =0.70, or toe pressure >30 mmHg. - Female subjects of childbearing potential must have a negative serum pregnancy test prior to first dose of study medication and must agree to use an effective method of contraception throughout the study. Females who are surgically sterile or have been postmenopausal for at least 1 year (12 consecutive months without menses) are exempted from these criteria. Effective methods of contraception include oral contraceptives, injectable or implantable hormonal methods, intrauterine devices, tubal ligation (if performed more than 1 year prior to screening), or double barrier contraception (e.g., diaphragm+condom). - Subject agrees to comply with ulcer care regimen for the duration of the study. - Subject is able to understand and sign an informed consent form and willing to comply with all study procedures. Exclusion Criteria: - Clinical signs and symptoms of infection of target ulcer assessed by clinical evaluation (the presence of infection is defined by =2 classic findings of inflammation or purulence). - Presence of cellulitis or gangrene on the lower leg or foot under study. - Presence of another open ulcer <2 cm away from target ulcer, on the same lower leg or foot. - Target ulcer on the heel. - Target ulcer caused primarily by untreated arterial insufficiency or with an etiology not related to diabetes. - Subjects with ulcers related to an incompletely healed amputation wound. - Acute or chronic osteomyelitis affecting the area of the target ulcer. - Any structural deformity of the lower leg or foot under study that would prevent off- loading of the target ulcer, including acute Charcot osteoarthropathy. - Previous use of a platelet-derived product (e.g., becaplermin) or other growth factors on the target ulcer within 4 weeks prior to Visit 1. - Previous use of autologous graft or allogeneic graft, or dermal substitute or living skin equivalent (e.g., Dermagraft® or Apligraf®) on the target ulcer or hyperbaric oxygen therapy within 2 weeks prior to Visit 1. - Use of any topical antimicrobials or enzymatic debridement treatment, to treat the target ulcer within 7 days prior to Visit 1. - Treatment with systemic corticosteroids other than for inhalation, immunosuppressive agents, radiation therapy, or chemotherapeutic agent within 30 days prior to Visit 1 or likelihood to receive any of these therapies during study participation. - History of cancer or current cancer, with the exception of adequately treated or excised non-melanoma skin cancer. - Vasculitis, connective tissue diseases, or any medical conditions known to impair ulcer healing, other than diabetes. - Sickle cell disease. - Clinically significant electrocardiogram (ECG) abnormality, as determined by the Investigator. - Any of the following laboratory results at screening: serum creatinine >2.5 mg/dL; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2x upper limit of normal (ULN). - Poor nutritional status (serum albumin < 2.5 g/dL). - A history of drug or alcohol abuse that could compromise compliance or safety. - History of human immunodeficiency virus (HIV) infection. - Known sensitivity to any component of BB-101 or placebo. - Participation in a clinical trial of an investigational drug or device within 30 days of study entry. - Pregnancy, lactation, or plans to become pregnant within 6 months. - Any social or medical condition that, in the opinion of the Investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives. - History of non-compliance with treatment or clinical visit attendance.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
BB-101
Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.

Locations

Country Name City State
Taiwan National Cheng Kung University Hospital Tainan

Sponsors (1)

Lead Sponsor Collaborator
Blue Blood Biotech Corp.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of local reactions To assess the incidence of local reactions for target ulcer and surrounding area and record the severity 6 weeks
Primary Incidence and severity of adverse events To assess the incidence of adverse events and record the severity 6 weeks
Primary Incidence of clinical laboratory abnormalities To assess the incidence of clinical laboratory abnormalities 6 weeks
Primary Change from baseline in ECG To assess the change of baseline in ECG 6 weeks
Primary Change from baseline in blood pressure To assess the change of baseline in in blood pressure 6 weeks
Primary Change from baseline in heart rate To assess the change of baseline in heart rate 6 weeks
Primary Change from baseline in body temperature To assess the change of baseline in body temperature 6 weeks
Primary Presence of anti-BB-101 antibodies To assess the immunogenecity for BB-101 6 weeks
Secondary Proportion of subjects with target ulcer that heals within the 4-week treatment period complete healing defined as re-epithelialization without drainage and dressing requirement 4 weeks
Secondary To evaluate plasma concentration of BB-101 To evaluate plasma concentration of BB-101 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04497805 - Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers Phase 2
Withdrawn NCT03675269 - Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer: N/A
Completed NCT04624516 - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence N/A
Not yet recruiting NCT06439667 - VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
Recruiting NCT05608187 - Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers Phase 2
Not yet recruiting NCT06437028 - Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers. N/A
Not yet recruiting NCT06278935 - Lifestyle Tailored Offloading for Diabetic Foot Ulcers N/A
Withdrawn NCT05024656 - AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers N/A
Terminated NCT02202668 - Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers N/A
Completed NCT01951768 - Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Phase 4
Terminated NCT01966380 - Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia Phase 2
Completed NCT01657474 - Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers N/A
Active, not recruiting NCT00389636 - TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers N/A
Completed NCT01181440 - Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers Phase 3
Enrolling by invitation NCT05888259 - Plantar Pressure Distribution in Diabetic Foot Ulcer N/A
Completed NCT04054804 - Digital Foot Check by Using the D-Foot, a New Software
Not yet recruiting NCT05877378 - Efficacy of PICO Single-use System in Chronic Ulcers N/A
Recruiting NCT06037369 - The Short Message-based Customized Standardized N/A
Completed NCT03312595 - Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) N/A
Recruiting NCT04564443 - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot N/A